Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Further strengthens BaseLaunch's global pharma industry partnerships
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Establishing Asymchem’s first manufacturing footprint in Europe
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Achira is engaged in development and commercialization of PoC medical test kits in India
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Subscribe To Our Newsletter & Stay Updated
